For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Oncolys Obtains Patent on Manufacturing Process for Anti-HIV Drug OBP-601 in Japan
May 2, 2014
- Nihon Chouzai Pharmaceutical Sales Reach 23,192 Million Yen in FY2013
May 1, 2014
- AZ Files for Domestic Approval of Bydureon Pen Formulation
May 1, 2014
- Chugai’s US Subsidiary Appoints Gianella-Borradori as Its Chief Medical Officer
May 1, 2014
- Takeda, Teva to Commercialize Teva’s Parkinson’s Disease Treatment Rasagiline in Japan
April 30, 2014
- Daiichi Sankyo Ceases PIII Study of Nimotuzumab for Lung Cancer in Japan
April 30, 2014
- Takeda to Introduce New Performance-Based Incentive Programs for Board of Directors, Senior Execs
April 30, 2014
- Kissei Taps Morozumi as New President, COO
April 30, 2014
- Chugai Discontinues Multinational PIII of Onartuzumab for Lung Cancer
April 30, 2014
- Hisamitsu Begins PI of Transdermal Schizophrenia Treatment in US
April 30, 2014
- Novel Anticancer Agent Trabectedin Meets Primary Endpoint of PFS in PII: Taiho
April 25, 2014
- MTPC Names Masayuki Mitsuka as New President
April 24, 2014
- Yoshindo, Lupin to Establish JV to Develop Etanercept Biosimilar, Start Clinical Trial in FY2014
April 24, 2014
- Ethical Drug Sales Jump 11.0% to Record 240.1 Billion Yen in 2013: Boehringer Japan
April 24, 2014
- Astellas Aims to Dominate SGLT-2 Inhibitor Market with Suglat
April 23, 2014
- Lilly Japan Starts PIII Study of Tadalafil for DMD Treatment
April 22, 2014
- Metal Objects Found in Voltaren Suppositories in Aichi Pref.: Novartis
April 22, 2014
- Nihon Generic Obtains Teva’s Manufacturing Plant, Eyeing Expansion of Production Capacity
April 22, 2014
- Entry into Japan Biosimilar Market Will Take Time, Says BI Chairman
April 21, 2014
- PIII Trial of Asthma Drug Benralizumab Kicks Off in Japan: Kyowa Kirin
April 21, 2014
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…